Glen Eagle Advisors’s GoodRx Holdings GDRX Stock Holding History

Glen Eagle Advisors’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-310	Closed	-$12.7K	–	997
2021 Q3	$12.7K	Hold	310	–	–	﹤0.01%	651
2021 Q2	$11.2K	Buy	310 +190	+158%	+$7.01K	﹤0.01%	672
2021 Q1	$4.68K	Buy	+120	New	+$5.4K	﹤0.01%	781

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Abdiel Capital Advisors New York $52M AUM 13.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

TCMX

Technology Crossover Management X Menlo Park, California $781M AUM 18.39% 1-Year Est. Return

Glen Eagle Advisors's GDRX Position: Q4 2021 in Review

Glen Eagle Advisors sold out of GoodRx Holdings (GDRX) in Q4 2021, closing a stake of 310 shares — an estimated $12.7K sold.

Glen Eagle Advisors first reported a position in GDRX in Q1 2021 and held it in 3 quarters. The position peaked at $12.7K in Q3 2021. 216 funds tracked by Wall St. Rank hold GDRX as of Q4 2021.

Glen Eagle Advisors reported no remaining GoodRx Holdings position as of Q4 2021 after selling out during the quarter.
Glen Eagle Advisors sold 310 GoodRx Holdings shares in Q4 2021, an estimated $12.7K.
Glen Eagle Advisors first reported a position in GoodRx Holdings in Q1 2021 and held it in 3 quarters.
Glen Eagle Advisors's GoodRx Holdings position peaked at $12.7K in Q3 2021.
216 funds tracked by Wall St. Rank held GoodRx Holdings as of Q4 2021.

Based on Glen Eagle Advisors's 13F filing for Q4 2021, filed 13 Aug 2024.